Pharming Group N.V. Sponsored ADR

PHAR Healthcare Biotechnology

Pharming Group N.V. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 26.6% from fiscal 2024. In the quarter to June 2026, revenue fell 3.22%, EPS fell 57.1%, free cash flow fell 183.9% and total debt rose 1.55%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

9.36 0.27 −2.80%
Market cap
$681.6M
P/E
62.4×
Fwd P/E
0.0×
Dividend yield
—
F-score
5/9
Altman Z
3.88
Beneish M
−2.78
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Cash and Short Term Investments
33.57 70.67 92.31 74.25 206.15 192.15 207.56 213.42 167.89 179.86
Receivables
11.99 12.27 18.39 28.83 35.90 29.98 27.62 46.16 54.82 54.70
Inventory
18.89 22.09 19.90 16.20 21.16 27.31 42.33 56.76 55.72 64.90
Other current assets
1.03 1.30 2.08 — — — — — — —
Total current assets
65.46 106.33 132.69 119.28 263.21 249.44 277.50 316.34 278.44 299.47
Property, Plant, Equpment (Net)
6.36 9.92 9.66 9.58 12.23 13.22 10.39 9.69 7.75 7.23
Long-Term Investments
0.26 1.61 1.38 6.17 7.12 8.65 9.73 10.40 4.23 8.65
Goodwill and Intangible Assets (Total)
59.66 68.23 60.27 79.31 94.08 83.83 75.12 71.27 61.04 135.54
Long Term Assets (Tax, Deferred)
— — — 32.02 31.88 21.22 22.97 29.76 30.54 31.02
Long-term assets (Other)
1.71 2.77 2.31 2.54 0.51 1.01 1.33 1.62 1.60 1.32
Total non-current assets
— — — 136.31 155.24 147.87 148.30 146.51 121.55 200.49
Total Assets
133.46 — 246.63 255.60 418.45 397.32 425.80 462.85 399.99 499.96
Accounts Payable
5.95 11.36 7.63 40.60 47.67 42.47 54.47 72.53 66.61 105.90
Current Part of Debt
27.79 27.30 40.80 51.06 2.04 1.88 1.77 1.82 4.25 5.34
Other current liabilities
20.34 34.52 46.50 20.28 25.18 34.85 45.57 — — 1.19
Total current liabilities
54.08 73.18 94.94 114.11 76.85 46.77 59.70 77.97 73.80 115.79
Long Term Debt (Total)
43.15 71.75 43.02 4.90 149.73 139.01 131.62 136.60 78.15 92.72
Non-current Revenue (Deferred)
2.39 1.77 0.77 — — — — — — —
Long Term Tax Liability (Deferred)
— (11.38) (40.22) — — — — — — —
Non-current Liabilities (Other)
4.92 34.12 36.82 19.36 0.21 0.17 — — — —
Total non-current liabilities
— — — 24.24 158.17 157.63 161.46 166.11 105.12 107.07
Total liabilities
104.54 180.82 175.65 138.35 235.02 204.40 221.16 244.07 178.92 222.86
Additional Paid In Capital
— — — 439.34 447.13 455.25 462.30 478.43 488.99 513.26
Common Stock (Net)
4.80 6.98 7.14 7.07 7.31 7.43 7.51 7.67 7.77 8.01
Retained Earnings
(293.71) (424.77) (383.49) (333.33) (295.62) (273.17) (256.43) (265.26) (275.49) (272.98)
Shareholders Equity (Other)
— — — 4.16 24.61 3.40 (8.74) (2.06) (0.21) 28.82
Common Equity (Total)
28.91 19.41 70.98 117.24 183.44 192.92 204.64 218.78 221.06 277.10
Shareholders Equity (Total)
28.91 19.41 70.98 117.24 183.44 192.92 204.64 218.78 221.06 277.10
Shareholders Equity and Liabilities (Total)
— — — 255.60 418.45 397.32 425.80 462.85 399.99 499.96
Shares (Common)
— — — 63.13 63.88 64.87 65.64 67.11 68.03 70.17
Shareholders Equity (Tangible)
— — — 37.93 89.35 109.08 129.52 147.51 160.02 141.56
Net Debt
37.37 28.38 (8.49) (18.29) (54.39) (51.26) (74.17) (75.00) (85.49) (81.81)
Total Debt
70.94 99.05 83.83 55.96 151.77 140.89 133.39 138.42 82.40 98.06

Fold the line items

In millions of $ except per-share values · columns are period end dates